Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3268314 | Endocrinology and Metabolism Clinics of North America | 2007 | 15 Pages |
Abstract
Several agents are currently being tested that target thyroid molecular signaling and cancer cell biology. The pathways involved include but are not limited to the Ras pathway, vascular endothelial growth factor and epidermal growth factor receptors and antibodies, angiogenesis inhibitors, tyrosine kinase inhibitors, heat shock protein inhibitors, demethylating agents, histone deacetylase inhibitors, and gene therapy. Each of these targeted approaches holds promise for our future ability to treat patients with thyroid cancer unresponsive to traditional therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Priya MD, Kenneth D. MD,